Patient Care Endocrinology & Cardiology - December 2007 - (Page 24)

I Polycystic ovary syndrome Continued from page 23 for the use of metformin in polycystic ovary syndrome. Lancet. 2003;361(9372):1894-1901. Gilbert C, Valois M, Koren G. Pregnancy outcome after first trimester exposure to metformin: a meta-analysis. Fertil Steril. 2006;86(3):658-663. Costello M, Shrestha B, Eden J, et al. Insulin-sensitising drugs versus the combined oral contraceptive pill for hirsutism, acne and risk of diabetes, cardiovascular disease, and endometrial cancer in polycystic ovary syndrome. Cochrane Database Syst Rev. 2007(1):CD005552. Brettenthaler N, De Geyter C, Huber PR, et al. Effect of the insulin sensitizer pioglitazone on insulin resistance, hyperandrogenism, and ovulatory dysfunction in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2004;89(8):3835-3840. Beck JI, Boothroyd C, Proctor M, et al. Oral anti-oestrogens and medical adjuncts for subfertility associated with anovulation. Cochrane Database Syst Rev. 2005;(1):CD002249. Kuhl H. Comparative pharmacology of newer progestogens. Drugs. 1996;51(2):188-215. Risser WL, Gefter LR, Barratt MS, et al. Weight change in adolescents who used hormonal contraception. J Adolesc Health. 1999; 24(6):433-436. Farquhar C, Lilford RJ , Marjoribanks J, et al. Laparoscopic “drilling” by diathermy or laser for ovulation induction in anovulatory polycystic ovary syndrome. Cochrane Database Syst Rev. 2007;(3):CD001122. I Preventing CHD in women Continued from page 16 7. Sibley C, Blumenthal RS, Bairey Merz CN, et al. Limitations of current cardiovascular disease risk assessment strategies in women. J Women’s Health. 2006;15:54-56. 8. Lichtenstein AH, Appel LJ, Brands M, et al. Diet and lifestyle recommendations revision 2006: a scientific statement from the American Heart Association Nutrition Committee. Circulation. 2006;114:82-96. 9. Godtfredsen NS, Osler M, Vestbo J, et al. Smoking reduction, smoking cessation, and incidence of fatal and non-fatal myocardial infarction in Denmark 1976–1998: a pooled cohort study. J Epidemiol Community Health. 2003;57:412-416. 10. Ranney L, Melvin C, Lux L, et al. Smoking cessation intervention strategies for adults and adults in special populations. Ann Intern Med. 2006;145:845-856. 11. Hill SE, Blakely T, Kawachi I, et al. Mortality among lifelong nonsmokers exposed to secondhand smoke at home: cohort data and sensitivity analyses. Am J Epidemiol. 2007;165:530–540. 12. Manson JE, Greenland PH, LaCroix AZ, et al. Walking compared with vigorous exercise for the prevention of cardiovascular events in women. N Engl J Med. 2002;347:716-725. 13. Lee IM, Rexrode KM, Cook NR, et al. Physical activity and coronary heart disease in women: is “no pain, no gain” passé? JAMA. 2001;285:1447-1454. 14. Fung TF, Willet WC, Stampfer MJ, at al. Dietary patterns and the risk of coronary heart disease in women. Arch Intern Med. 2001;161:18571862. 15. Mensink RP, Zock PL, Kester ADM, et al. Effects of dietary fatty acids and carbohydrates on the ratio of serum total to HDL cholesterol and on serum lipids and apolipoproteins: a meta-analysis of 60 controlled trials. Am J Clin Nutr. 2003;77:1146-1155. 16. Li TY, Rana JS, Manson JE, et al. Obesity as compared with physical activity in predicting risk of coronary heart disease in women. Circulation. 2006;113;499-506. 17. Van Gaal LF, Mertens IL, DeBlock CE. Mechanisms linking obesity with cardiovascular disease. Nature. 2006;444:875-880. 18. Jackson L, Leclerc J, Erskine Y, et al. Getting the most out of cardiac rehabilitation: a review of referral and adherence predictors. Heart. 2005;91;10-14. 19. Jenkinson M, Madeley J, Mitchell JRA. The influence of psychosocial factors on survival after myocardial infarction. Public Health. 1993;107:305-317. 20. Carney RM, Blumenthal JA, Freedland KE, et al. Depression and late mortality after myocardial infarction in the Enhancing Recovery in Coronary Heart Disease (ENRICHD) study. Psychosomatic Medicine. 2004;66:466-474. 21. Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial Collaborative Research Group. Diuretic versus alpha-blocker as first-step antihypertensive therapy: final results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Hypertension. 2003;42:239-246. 22. Grundy SM, Cleeman JI, Bairey Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Circulation. 2004;110:227-239. 23. Ridker PM, Cook NR, Lee IM, et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med. 2005;352:1293-1304. 24. Chan AT, Manson JE, Feskanich D, et al. Long-term aspirin use and mortality in women. Arch Intern Med. 2007;167:562-572. 25. Magliano D, Rogers S, Abramson M, et al. Hormone therapy and cardiovascular disease: a systematic review and meta-analysis. BJOG. 2006;113:5-14. 26. Bonaa KH, Njolstad I, Ueland PM, et al. NORVIT Trial Investigators. Homocysteine lowering and cardiovascular events after acute myocardial infarction. N Engl J Med. 2006;354:1578-1588. 31. 32. 33. 34. 35. 36. 37. 24 PATIENT CARE ENDOCRINOLOGY & CARDIOLOGY www.patientcareonline.com http://www.patientcareonline.com

Table of Contents Feed for the Digital Edition of Patient Care Endocrinology & Cardiology - December 2007

Patient Care Endocrinology & Cardiology - December 2007 Research Digest Contents Medicine in the News Options for Managing Diabetes: Three Types of Basal Insulin Therapy Using the New AHA Guidelines for Preventing Coronary Heart Disease in Women Cardiovascular and Metabolic Implications of Polycystic Ovary Syndrome Case & Comment Classified Advertising Clinical Clips

Patient Care Endocrinology & Cardiology - December 2007

For optimal viewing of this digital publication, please enable JavaScript and then refresh the page. If you would like to try to load the digital publication without using Flash Player detection, please click here.